Envoy Medical, Inc. — Form 8-K Summary
Filing date: October 20, 2023; earliest reported event: October 16, 2023. The filing reports an executive employment agreement and does not contain financial statements or operating results.
Business Context and Reporting Period
Envoy Medical, Inc. is a Delaware company whose Class A common stock and redeemable warrants trade on Nasdaq under the symbols COCH and COCHW. The company reported entering into a new employment agreement with Chief Executive Officer Brent T. Lucas through its wholly owned subsidiary, Envoy Medical Corporation.
Key Financial and Operating Metrics
- No revenue, profit, cash flow, margin, debt, liquidity, or other operating metrics are provided in this filing.
- The agreement provides for an initial annual base salary of $400,000.
- The initial employment term is five years, subject to earlier termination.
- Mr. Lucas is eligible for cash and equity incentive compensation as approved by the Compensation Committee.
Material Changes and Compensation Terms
- The agreement may be terminated by either party at any time upon written notice.
- If the company terminates employment without Cause or Mr. Lucas terminates for Good Reason, the company generally must provide one year of then-current base salary, a prorated portion of previously approved annual cash incentive compensation, health insurance coverage for up to two years or until new employer coverage begins, and payment of executive search firm costs.
- If employment ends because of Mr. Lucas’s death or disability, he or his beneficiaries will receive an amount equal to his then-current annual base salary.
- The agreement also provides eligibility for paid time off and employee benefits generally available to company employees.
Outlook, Risks, Contingencies, and Unusual Items
The principal potential financial obligation disclosed is the severance and benefits package payable upon specified termination events. The agreement’s definitions of “Cause” and “Good Reason,” as well as the complete terms governing incentives and termination, should be reviewed in Exhibit 10.1. No business outlook or financial guidance is included.
Investor Verification Items
- Review Exhibit 10.1 for the full employment agreement, including termination definitions and any restrictive covenants.
- Assess the potential cost and timing of severance, benefits continuation, and executive search expenses.
- Monitor future filings for equity or cash incentive awards approved for the CEO.
- Consult subsequent periodic reports for the company’s financial condition, liquidity, and operating performance, which are not addressed in this Form 8-K.